Search

Danaher Corp

Fermé

SecteurSoins de santé

191.98 -0.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

189.24

Max

193.94

Chiffres clés

By Trading Economics

Revenu

-168M

1B

Ventes

-887M

6B

P/E

Moyenne du Secteur

39.511

62.58

BPA

2.06

Rendement du dividende

0.67

Marge bénéficiaire

17.291

Employés

58,000

EBITDA

-560M

1.5B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+14.17% upside

Dividendes

By Acuity

Rendement du dividende

Moyenne du Secteur

0.67%

2.19%

Prochains Résultats

20 oct. 2026

Date du Prochain Dividende

31 juil. 2026

Date du Prochain Détachement de Dividende

25 sept. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

4B

142B

Ouverture précédente

192.08

Clôture précédente

191.98

Sentiment de l'Actualité

By Acuity

47%

53%

151 / 340 Classement par Healthcare

Danaher Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 juil. 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 juil. 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 juil. 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 juil. 2026, 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 juil. 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Comparaison

Variation de prix

Danaher Corp prévision

Objectif de Prix

By TipRanks

14.17% hausse

Prévisions sur 12 Mois

Moyen 219.78 USD  14.17%

Haut 240 USD

Bas 195 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

17

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

151 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat